Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Novo has said a new contract with CVS Health Corp. for its blockbuster Wegovy would drive volume from July 1, yet it still ...

CVS acknowledged that Zepbound has been shown to help people lose more weight than Wegovy, but that Wegovy can still help ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay programs at $499 monthly ...

Novo Nordisk A/S's Wegovy, a semiglutide injectable medicine, is now the primary weight loss drug offered on CVS's standard formulary, a list of medications an insurance plan covers. The news was not ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will need to show more robust growth in the months ahead to bolster market ...

Eli Lilly and Company (NYSE:LLY) is one of the high-margin pharma stocks to buy now. Eli Lilly and Company (NYSE:LLY) is set ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...